Please login to the form below

Not currently logged in
Email:
Password:

IBD

This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.

Finch’s microbiota drug for C. diff gets FDA breakthrough status

Finch’s microbiota drug for C. diff gets FDA breakthrough status

Finch's CEO Mark Smith. Led by CEO Mark Smith, the company also has a two-year-old deal with Takeda to develop a microbiota treatment for irritable bowel disease (IBD).

Latest news

  • BMS to test Vedanta’s bacterial therapy with Opdivo BMS to test Vedanta’s bacterial therapy with Opdivo

    The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... VE202 is based on the idea that IBD patients are deficient in certain Clostridia species in

  • Communiqué: big wins for obesity and sugar tax campaigners Communiqué: big wins for obesity and sugar tax campaigners

    Specialist healthcare communications group Sciterion (pictured below) won the Excellence in Communications via a Live Event or Stand-Alone Activity accolade for its Live Multi-site National IBD Meeting. ... Meanwhile, Aurora Healthcare Communications’

  • Communiqué 2018 - all the winners Communiqué 2018 - all the winners

    Excellence in Communications via a Live Event or Stand-Alone Activity. Live Multi-site National IBD Meeting by Sciterion for AbbVie. ... Travel with IBD by Aurora Healthcare Communications for Takeda and Crohns Colitis UK.

  • Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

    therapies. Genentech is tapping into the Cambridge, UK-based company’s expertise by using its precision metagenomics microbiome platform to analyse patient samples from clinical trials of its investigational IBD medicines. ... This will allow

  • Pfizer’s Xeljanz picks up a third indication in the US Pfizer’s Xeljanz picks up a third indication in the US

    that could strengthen Pfizer’s stance in the inflammatory bowel disease (IBD) market. ... Continuing this trend, Xeljanz is also the first and only JAK inhibitor approved in the US to treat UC, and an approval in the IBD therapy area for this

More from news
Approximately 11 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD).  . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)

  • Deal Watch June 2016 Deal Watch June 2016

    IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.

  • Deal Watch October 2015 Deal Watch October 2015

    Janssen's partnership with Canadian biotech enGene, facilitated through J&J Innovation, brings gene therapies for inflammatory bowel disease (IBD) and includes an undisclosed upfront payment and equity investment, R&D ... Research collaboration, option,

  • Pharma deals in June 2015 Pharma deals in June 2015

    the treatment of inflammatory bowel disease (IBD). ... 130. Lycera Corporation/ Celgene Corporation. Orally bioavailable RORgamma agonists for ex vivo use lead programme, LYC-30937  (oral gut-directed ATPase modulator for IBD, p1).

  • Getting real about patient support Getting real about patient support

    opposed to a series of acute episodes (such as in asthma, COPD or IBD).

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...
Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...

Infographics